A2A Panelist

Updated: Feb 7, 2020

A2A Founder & CEO Edward Painter was a panelist at BIO Investor forum panel entitled "Applying artificial intelligence to improve therapy development today"

May 27, 2025 - A2A Pharmaceuticals a clinical stage oncology company with the lead asset AO-252, a PPI inhibitor of TACC3 which is a 1st...

Biomea Fusion, Inc., a precision oncology company dedicated to developing innovative medicines targeting genomically defined alterations...

Couldn’t Load Comments

It looks like there was a technical problem. Try reconnecting or refreshing the page.